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poor disease control despite high doses of inhaled
corticosteroids and additional therapy, leading to personal
suffering, early deterioration of lung function, and
significant consumption of health care resources. If no
exacerbating factors, such as smoking or allergies, are
found after extensive investigation, these children are given
a diagnosis of therapy-resistant (or therapy-refractory)
asthma (SA).
Objective: We sought to deepen our understanding of childhood
SA by analyzing gene expression and modeling the underlying
regulatory transcription factor networks in peripheral blood
leukocytes.
Methods: Gene expression was analyzed by using Cap Analysis
of Gene Expression in children with SA (n 5 13), children with
controlled persistent asthma (n 5 15), and age-matched healthy
control subjects (n 5 9). Cap Analysis of Gene Expression
sequencing detects the transcription start sites of known and
novel mRNAs and noncoding RNAs.
Results: Sample groups could be separated by hierarchical
clustering on 1305 differentially expressed transcription start
sites, including 816 known genes and several novel transcripts.
Ten of 13 tested novel transcripts were validated by means of
RT-PCR and Sanger sequencing. Expression of RAR-related
orphan receptor A (RORA), which has been linked to asthma in
genome-wide association studies, was significantly upregulated
in patients with SA. Gene network modeling revealed decreased
glucocorticoid receptor signaling and increased activity of the
mitogen-activated protein kinase and Jun kinase cascades in
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638Conclusion: Circulating leukocytes from children with
controlled asthma and those with SA have distinct gene
expression profiles, demonstrating the possible development of
specific molecular biomarkers and supporting the need for novel
therapeutic approaches. (J Allergy Clin Immunol 2015;136:638-
48.)
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Asthma is the most common chronic disease in children1 and
can be defined as mild, moderate, or severe depending on the
extent of medication needed to control symptoms.2 Problematic
severe asthma is characterized by poor disease control, even
with high doses of inhaled corticosteroids and additional
therapies. It affects approximately 5% of all asthmatic children3
and can cause extensive personal suffering, early deterioration
of lung function, and significant consumption of health care
resources.4 Problematic severe asthma in children can often be
explained by exposure to exacerbating factors in the environment,
such as smoking or allergens, but therapy-resistant (or therapy-
refractory) asthma (SA) is believed to exist in a subgroup of chil-
dren in whom no such factors are found, despite extensive
investigation.5
Global gene expression in human asthma has been studied in
isolated leukocyte populations,6-9 bronchial and epithelial biopsy
specimens,10-14 and nasal lavage samples.15 These studies have
provided important mechanistic insights for mild-to-moderate
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Our aim in the present study was to identify the gene pathways
that are deregulated in children with SA. Therefore we analyzed
gene expression in peripheral blood leukocytes from children
with SA (n5 13) and controlled persistent asthma (CA; n5 15),
as well as age-matched healthy control subjects (CTRLs; n5 9).
We used Cap Analysis of Gene Expression (CAGE), a technology
based on next-generation sequencing that quantitatively measures
gene expression for individual transcription start sites (TSSs),
including mRNAs and long noncoding RNAs.19 The asthmatic
children were selected from Swedish Search, a national
multicenter, cross-sectional study that aims to identify children
with problematic severe asthma and characterize those who are
difficult to treat or resistant to therapy.20 Although these samples
had previously been analyzed with expression microarrays,21 we
reasoned that the promoter-level resolution of CAGE sequencing
data and the unbiased detection of novel genes and alternative
promoters could provide new and interesting information.METHODS
Children with CA (n 5 15) and SA (n 5 13) were selected from the
Swedish Search study; details on inclusion criteria and clinical examination
procedures are described elsewhere.20,21 CTRLs (n 5 9) were recruited at
Astrid Lindgren Children’s Hospital, Stockholm, Sweden, from children
admitted for elective surgical procedures unrelated to asthma. Buffy coat
isolation from blood samples and RNA extraction were described
previously.21 For statistical analysis of clinical parameters, normally
distributed data are summarized by means and SDs and compared by using
the Student t test. Nonnormally distributed data are presented as medians
and interquartile ranges and compared with the Mann-Whitney U test.
A comprehensive description of the methods used in this study is provided
in the Methods section in this article’s Online Repository at www.
jacionline.org. Primers for validation of novel TSSs are listed in Table E1 in
this article’s Online Repository at www.jacionline.org. Informed consent
was obtained from all participating children and their parents, and the study
was approved by the local ethics committee.RESULTS
We analyzed the transcriptome of peripheral blood leukocytes
from children with CA (n 5 15) and those with SA (n 5 13), aswell as age-matched CTRLs (n 5 9) using CAGE sequencing.
The asthmatic children were selected from the Swedish Search
study,20 and all cases of SA had been classified as SA in the
absence of any identified aggravating factors. Most clinical
variables did not differ between the CA and SA groups, but
children with SA had significantly stronger responses to
methacholine provocation and increased blood neutrophil
counts compared with those with CA (Table I), as previously re-
ported in children with severe asthma.22 Leukocyte cell counts
are provided for individual samples in Table E2 in this article’s
Online Repository at www.jacionline.org. A flow chart illus-
trating the different analyses performed in this article is pro-
vided in Fig E1 in this article’s Online Repository at www.
jacionline.org.CAGE measures gene expression at the TSS of
known and novel transcripts
CAGE sequencing detects the 59 end of transcripts with a 59
7-methylguanosine cap, such as mRNAs and many long
noncoding RNAs. Use of the HeliScope single-molecule
sequencer (Helicos BioSciences, Cambridge, Mass) bypasses
the need for PCR amplification of sample libraries to produce
highly quantitative expression data.19 Expression for a particular
TSS is estimated by grouping nearby sequencing reads (tags) after
mapping to the human genome to tag clusters (TCs) and counting
the number of reads within each cluster. Sequencing library sizes
are shown in Table E2. We limited expression analysis to a set of
45635 TCs that were detected by at least 3 reads in at least 9 sam-
ples (ie, the size of the smallest sample group). When compared
with GENCODE23 transcript annotation, 49% of the TCs mapped
within 500 bp of a known TSS, and another 24%mapped in exons
of known genes. A further 27% of the TCswere not located within
exons of known coding or noncoding genes; thesemight represent
novel genes or transcript isoforms. TC annotation is summarized
in Fig E2 in this article’s Online Repository at www.jacionline.
org.Children with CA and those with SA have distinct
gene expression profiles and cluster separately
We performed differential expression analysis for all pairwise
comparisons: children with CA versus CTRLs, children with SA
versus CTRLs, and childrenwith SAversus thosewith CA.A total
of 1305 TCs were differentially expressed with a Benjamini-
Hochberg–adjusted P value of less than .1 in any comparison, and
1029 of thesemapped to 816 unique gene symbols (ie, some genes
had >1 cluster). The remaining TCs were intergenic, intronic, or
antisense to known transcripts. Hierarchical clustering of the
samples based on differentially expressed TCs clearly separated
the sample groups, with the exception of a single CTRL sample
that clustered with the SA group (Fig 1). Statistically significant
TCs with GENCODE transcript annotation are provided in
Tables E3-E5 in this article’s Online Repository at www.
jacionline.org.
These results imply that differences in the underlying disease
biology of CA and SA are reflected as distinct molecular
fingerprints. However, because we measured gene expression
for a complex population of leukocytes, the profiles also reflect
differences in cell composition between sample groups, such as
the significantly increased neutrophil counts in children with
TABLE I. Clinical characteristics of the included samples
CTRLs Children with CA Children with SA P value
No. of subjects 9 15 13
Age (y), mean (SD) 11 (5) 13 (3) 14 (3) NS
Female sex (%) 11 40 38 NS
BMI (%), median (IQR) 59 (36-66) 62 (32-76) 77 (61-93) NS
ACT score, mean (SD) NA 24 (1) 16 (3)
ICS (mg), median (IQR) NA 320 (180-400) 800 (800-800)
FEV1 (% predicted), mean (SD) NA 86 (11) 88 (22) NS
DRSmethacholine, median (IQR) NA 0.8 (0.2-8.0) 11.1 (1.7-61.0) .015 (CA-SA)
FENO (ppb), median (IQR) NA 13 (9-21) 18 (11-38) NS
Total IgE (kUA/L), median (IQR) NA 200 (66-795) 500 (120-1000) NS
Atopic* (%) NA 80 85 NS
Total WBC (109 3 L-1), mean (SD) 5.8 (0.8) 5.9 (1.5) 6.7 (2.2) NS
Eosinophils (109 3 L-1), mean (SD) 0.2 (0.1-0.2) 0.2 (0.2-0.4) 0.4 (0.2-0.4) NS
Lymphocytes (109 3 L-1), mean (SD) 2.4 (0.6) 2.7 (0.6) 2.3 (0.7) NS
Monocytes (109 3 L-1), mean (SD) 0.4 (0.1) 0.5 (0.2) 0.4 (0.1) NS
Neutrophils (109 3 L-1), mean (SD) 2.6 (0.5) 2.5 (0.7) 3.5 (1.6) .046 (CA-SA)
ACT, Asthma Control Test; BMI, body mass index; DRSmethacholine, slope of the dose-response curve for methacholine provocation; FENO, fraction of exhaled nitric oxide; ICS,
inhaled corticosteroids; IQR, Interquartile range; NA, not available; NS, not significant.
*Atopy is defined as a specific IgE level of greater than 0.35 kU/L to inhalant allergens (Phadiatop).
Mann-Whitney U test.
Student t test.
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further using the generalized linear model (GLM) methods in
edgeR,24 applying a model that incorporated both sample
groups and neutrophil, eosinophil, and lymphocyte blood
counts as fractions of the total number of white blood cells.
This adjusted the expression levels for differences in cell counts
among samples but also removed TCs that varied with both
sample groups and neutrophil counts, resulting in a conserva-
tive set of TCs that were differentially expressed, irrespective
of cell composition. A total of 680 TCs were differentially ex-
pressed, with an adjusted P value of less than .1 in any compar-
ison, and 503 of these mapped to 460 unique gene symbols.
Hierarchical clustering and Venn diagrams illustrating the over-
lap between the 2 differential expression analyses are shown in
Figs E3 and E4 in this article’s Online Repository at www.
jacionline.org, respectively. Statistically significant TCs with
GENCODE transcript annotation are provided in Tables E6-
E8 in this article’s Online Repository at www.jacionline.org.
Because our patient groups were comparatively small, we
assessed statistical power for our current sample size and false
discovery rates and obtained consistent power predictions of
between 0.4 and 0.5. By randomizing sample group labels, we
found the rate of false-positive results among differentially
expressed TCs to be practically zero. Combining these analyses
(see Figs E5 and E6 in this article’s Online Repository at www.
jacionline.org), we conclude that although identification of
marker genes between disease groups is somewhat limited by
the statistical power at these sample sizes, we can still identify
a stable set of biomarker genes.Genes differentially expressed between children
with SA and those with CA also distinguish severe
from nonsevere asthma in adults
We tested these results on an independent set of publicly
available gene expression microarray data for CD41 and CD81
T cells from adults with severe and nonsevere asthma.16 The
original study found activation of CD81 T cells in patients withsevere asthma but only minor differences for CD41 cells and
no significant difference between patients with nonsevere asthma
and CTRLs. We selected all available microarray probes for
GENCODE transcripts with a differentially expressed TC in our
analysis (1537 probes for 698 of 1305 TCs from pairwise
comparisons between sample groups) and clustered the
expression profiles of the 2 T-cell types separately. Although
our set of differentially expressed transcripts was derived from
mixed leukocytes from children, it could still separate CD81 T
cells from adults with severe and those with nonsevere asthma,
and results were similar for differentially expressed transcripts
from theGLM analysis (see Figs E7 and E8 in this article’s Online
Repository at www.jacionline.org). Bootstrapping analysis of the
stability of the separation between groups is shown in Fig E9 in
this article’s Online Repository at www.jacionline.org. These
results suggest that the differences in gene expression reflect
the underlying disease dysregulation and that there are molecular
similarities between SA in children and severe asthma in adults. It
also hints that some of the differential expression we see is likely
to depend on CD81 rather than CD41 T cells. Finally, it shows
that results from CAGE sequencing can be transferred to another
technology and that these transcripts are applicable as markers in
another sample set.Increased activity of natural killer cells and genes
involved in leukocyte migration in children with SA
To explore the biology underlying the differentially expressed
TCs, we annotated them with gene symbols and searched for
Gene Ontology (GO) term and pathway (Kyoto Encyclopedia of
Genes and Genomes [KEGG]) enrichment using GOseq.25
Table II lists a selection of significant terms (adjusted P <
.05) and their associated genes. Because some of these might
result from cell count differences, we also analyzed enrichment
for the GLM analysis of differential expression. Few GO terms
and KEGG pathways were significantly enriched in this anal-
ysis, partly because of the smaller number of differentially ex-
pressed genes. Most likely, this is also because many
FIG 1. Hierarchical clustering based on 1305 TCs differentially expressed in any of the 3 pairwise
comparisons of CTRLs versus children with CA, CTRLs versus children with SA, or children with CA versus
those with SA. The distance measure for clustering of samples and TCs (expression in normalized tags per
million reads [tpm]) was Spearman rank correlation.
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represent differences in sample composition. Categories that
retain significance (adjusted P < .1) are marked in Table II.
Both children with CA and those with SA displayed activation
of genes involved in natural killer (NK) cell–mediated cytotox-
icity, but the differentially expressed genes differed. Fig E10 in
this article’s Online Repository at www.jacionline.org shows
differences in NK cell signaling between the 2 patient groups
in a KEGG pathway diagram.
Experimental validation of novel transcripts and
alternative TSSs
Using CAGE sequencing, we could also detect novel
transcripts and alternative TSSs. Combined bioinformatic
analysis and manual curation identified a high-confidence set
of 13 candidate novel TSSs for experimental validation
(Table III). Ten of these could be detected by using RT-PCR
for 2 CTRL samples, and all 10 were further confirmed by
means of Sanger sequencing (see Fig E11 in this article’s
Online Repository at www.jacionline.org). Fig 2 shows
examples of validated novel TSSs with mean expression acrosssamples and supporting sequence data, including an alternative
first exon for Rho GTPase activating protein 15 (ARHGAP15),
which has been called a ‘‘master negative regulator of
neutrophil functions.’’26 Both known and novel TSSs were
upregulated in children with SA versus CTRLs, irrespective
of adjustment for sample leukocyte composition, and also
between children with SA and those with CA in the classical
analysis of differential expression (see Fig E12 in this article’s
Online Repository at www.jacionline.org). The novel first exon
for ARHGAP15 is spliced to the second exon of the annotated
transcript upstream of the open reading frame. Expression in
sorted leukocyte populations from the FANTOM5 project27
suggests that most of the novel TSSs are expressed in
neutrophils and eosinophils (see Fig E13 in this article’s Online
Repository at www.jacionline.org).Comparison of differentially expressed TCs with
genetic associations in asthmatic patients
We compared the genomic coordinates of our differentially
expressed TCs with single nucleotide polymorphisms (SNPs)
TABLE II. Representative GO terms and KEGG pathways enriched among differentially expressed genes
GO/KEGG ID GO/KEGG name Adjusted P value Genes
Upregulated in children with SA vs those with CA
KEGG:04666 FcgR-mediated phagocytosis 8.992e-06 ARPC1B, ARPC2, ASAP1, DOCK2, FCGR2A, GAB2, LIMK2, LYN, MAPK1,
MARCKS, PAK1, PIK3R5, PLCG2, PRKCB, PRKCD, VASP, WAS
KEGG:04810* Regulation of actin cytoskeleton 2.109e-04 ARPC1B, ARPC2, CYFIP2, FGD3, IQGAP1, IQGAP2, ITGAL, LIMK2,
MAPK1, MSN, MYL12A, PAK1, PAK2, PIK3R5, PIKFYVE, PXN,
RHOA, SOS2, SSH2, TIAM2, WAS
KEGG:04380 Osteoclast differentiation .002 FCGR2A, FOS, FOSL2, GAB2, JUNB, LILRA2, MAP2K6, MAPK1,
NCF2, NCF4, NFATC1, PIK3R5, PLCG2, SPI1, TGFBR2
KEGG:4670* Leukocyte transendothelial migration .003 GNAI2, ITGAL, MSN, MYL12A, NCF2, NCF4, PIK3R5, PLCG2, PRKCB,
PXN, RHOA, VASP
KEGG:4062 Chemokine signaling pathway .007 ARRB2, DOCK2, GNAI2, GNG2, LYN, MAPK1, PAK1, PIK3R5, PREX1,
PRKCB, PRKCD, PXN, RHOA, SOS2, TIAM2, WAS
KEGG:5140 Leishmaniasis .011 CR1, FCGR2A, FOS, MAPK1, NCF2, NCF4, PRKCB, PTPN6, TLR4
KEGG:4662 B-cell receptor signaling pathway .021 DAPP1, FOS, LYN, MAPK1, NFATC1, PIK3R5, PLCG2, PRKCB, PTPN6,
SOS2
KEGG:5100 Bacterial invasion of epithelial cells .021 ARPC1B, ARPC2, GAB1, HCLS1, PIK3R5, PXN, RHOA, RHOG, WAS
KEGG:5150 Staphylococcus aureus infection .021 C5AR1, FCGR2A, FPR1, ITGAL, PTAFR, SELPLG
KEGG:4650* NK cell–mediated cytotoxicity .025 CD48, ITGAL, MAPK1, NFATC1, PAK1, PIK3R5, PLCG2, PRKCB, PTPN6,
SOS2, TNFRSF10C
Downregulated in children with SA vs those with CA
GO:0030852 Regulation of granulocyte
differentiation
.017 GFI1B, IKZF1, OGT, RARA
GO:0046649 Lymphocyte activation .044 ATM, BCL11B, CD3G, CSK, FKBP1A, GRAP2, IKZF1, IKZF3, ITPKB,
LAT, MS4A1, PIK3R1, RARA, TRAC
Upregulated in children with SA vs CTRLs
KEGG:4730 Long-term depression .030 GNAQ, IGF1R, ITPR2, PLCB1, PRKCB
Downregulated in children with SA vs CTRLs
KEGG:3010* Ribosome 1.399e-04 RPL11, RPL13, RPL27, RPL27A, RPL3, RPL35, RPL35A, RPL37A,
RPLP2, RPS11, RPS21, RPS27, RPSA
GO:0045944 Positive regulation of transcription
from RNA polymerase II promoter
.028 BCL11B, DDX17, EGR1, EGR2, FOXO3, IKZF1, MED10, NFIX, SOX4,
UTF1
Upregulated in children with CA vs CTRLs
KEGG:4650* NK cell–mediated cytotoxicity 6.332e-06 CD247, GZMB, NCR3, PRF1, SH2D1B, ZAP70
Downregulated in children with CA vs CTRLs
KEGG:4380 Osteoclast differentiation .010 FOS, FOSB, JUNB, NFKBIA, SPI1
GO:0006357 Regulation of transcription from
RNA polymerase II promoter
1.168e-05 CSDA, EGR1, EGR2, ETS2, FOS, FOSB, ID1, JUNB, KLF13, NFIL3,
NFKBIA, PLK3, RXRA, SPI1, TXNIP, ZFP36
GO:0006955 Immune response .007 AMICA1, AQP9, C5AR1, CD83, DUSP6, EGR1, FOS, NFIL3, NFKBIA,
PTEN, TXNIP
GO:0008219 Cell death .021 CSDA, DUSP6, EGR3, EIF4G2, ID1, IRS2, NFKBIA, PLK3, PREX1,
PTEN, RXRA, SRGN, TXNIP
*Adjusted P < .1 after adjustment for cell counts in the GLM analysis.
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tion studies. HaploReg v228 was used to identify linkage
disequilibrium (LD) blocks for 62 SNPs with genome-wide sig-
nificant association with asthma from 17 studies.29 Two differ-
entially expressed TCs from the classical differential
expression analysis overlapped LD blocks associated with
asthma in European populations that were located in the IL-6
receptor (IL6R)30 and IL-2 receptor b (IL2RB)31 genes (see
Tables E9 and E10 in this article’s Online Repository at
www.jacionline.org). Both TCs were upregulated 3-fold in chil-
dren with SA compared with those with CA but were not differ-
entially expressed between children with CA and CTRLs.
A third TC in absent in melanoma 2 (AIM2) overlapped an
LD block associated with asthma in subjects of African
descent.32 Furthermore, 2 differentially expressed TCs were
in the genes GRB2-associated binding protein 1 (GAB1)33and RAR-related orphan receptor A (RORA),31 which have
been previously associated with asthma, although not within
the association blocks. Only the TC in RORA was significantly
differentially expressed in the cell count–adjusted (GLM) anal-
ysis, which also included 2 differentially expressed TCs in PY-
HIN1 and IFI16, both of which were located in the same LD
block as AIM2.32 Expression levels for these clusters are shown
in Fig E14 in this article’s Online Repository at www.
jacionline.org. Additionally, an SNP 225 bp upstream of the
cluster in IL2RB, rs228954, overlaps a DNase I hypersensitivity
signal34 and is predicted to change a binding motif for the
peroxisome proliferator-activated receptors.35,36 Interestingly,
rs2284033, an SNP located 1.6 kb upstream of the cluster, is
predicted to alter a binding site for RORA. The small overlap
between differentially expressed TCs and associated
genetic variants supports the concept that transcriptional
TABLE III. Differentially expressed novel TSSs (adjusted P < .1) selected for experimental validation by using RT-PCR and Sanger
sequencing
TSS Gene Mean tpm
Log fold change
Validated
CTRLs vs
children with CA
CTRLs vs
children with SA
Children with
CA vs those with SA
Alternative TSSs
chr2:24714142(1) NCOA1 57 NS NS 0.39 No
chr2:143828538(1)* ARHGAP15 175 NS 0.97 0.99 Yes
chr4:148973914(1) ARHGAP10 3 NS NS 21.02 Yes
chr8:131370837(2) ASAP1 105 NS NS 0.57 No
chr9:117160251(2) AKNA/RP11-9M16.2 5 NS NS 0.63 Yes
chr13:46948966(2) KIAA0226L 25 NS 0.94 NS Yes
chr15:86087320(1)* AKAP13 30 NS 0.78 0.63 Yes
chr16:90023689(1) DEF8 35 NS NS 0.43 Yes
chr17:8316490(1)* NDEL1 137 NS 0.61 0.68 Yes
Novel transcripts
chr6:105901520(1) Possibly lincRNA 4 NS NS 21.01 No
chr12:8605756(2)* Possibly lincRNA 5 NS NS 0.93 Yes
Antisense transcripts
chr3:134314106(1) KY 33 NS NS 0.58 Yes
chr14:95652012(1) CLMN/CTD-2240H23.2 19 NS NS 0.52 Yes
Coordinates represent the first nucleotide of the transcript, with the genomic strand in parentheses.
NS, Not significant; tpm, tags per million reads.
*Significantly differentially expressed also after adjustment for cell counts.
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at disease onset.37Distinct transcription factor networks regulate gene
expression in children with CA and those with SA
Because CAGE measures gene expression by sequencing
TSSs, the data are well suited for promoter analysis. We applied
Motif Activity Response Analysis (MARA)38 to model the
regulatory networks underlying gene expression profiles.
MARA combines prediction of transcription factor (TF) binding
sites with mathematic modeling of changes in gene expression
to calculate the global importance of TF binding sites for
driving gene expression in a given sample. We analyzed prox-
imal promoter regions from 300 bp upstream to 100 bp down-
stream of TCs and a wider promoter region from 1 kb
upstream to 200 bp downstream. We limited the analysis to
TCs near known TSSs plus our high-confidence set of novel
TSSs and again used linear models to adjust for sample leuko-
cyte composition. This produces a conservative estimate of dif-
ferences between sample groups, excluding also motifs varying
with both group and cell counts. This adjustment is especially
important because we aim to infer regulatory relationships be-
tween TFs and target genes occurring within a cell. The top
10 significant motifs (adjusted P < .1) from pairwise compari-
sons of motif activities between sample groups are shown in
Table IV for the wider promoter region (see Table E11 in this
article’s Online Repository at www.jacionline.org for the prox-
imal promoter region). Box plots illustrating motif activities
within sample groups are shown in Figs E15-E17 in this arti-
cle’s Online Repository at www.jacionline.org. Expression pro-
files of the TFs corresponding to the motifs in Table IV are
shown in Fig E18 in this article’s Online Repository at www.
jacionline.org for sorted leukocyte populations from the
FANTOM5 project.27 Fig 3 shows the regulatory network formotifs with significantly different activity between children
with CA and those with SA. Differences in gene expression be-
tween these 2 types of asthma appear to be determined by 2
internally highly connected TF modules. One of these has
higher activity in children with SA than in those with CA and
includes motifs for TFs, such as GTF2I, HIC1, PAX5, and the
MYF and TFAP2 families. The other module, which includes
motifs for TFs, such as ZNF148 and the NFY family, has
decreased activity in children with SA compared with those
with CA. Notably, motif activity for the glucocorticoid receptor
(NR3C1) was also lower in children with SA. Regulatory net-
works for the proximal promoter region and the other (children
with CA vs CTRLs and children with SA vs CTRLs) are shown
in Figs E19-E23 in this article’s Online Repository at www.
jacionline.org.GO and pathway analyses highlight the roles of
individual TFs
To understand the function of these TFs in our samples, we
analyzed GO term and KEGG pathway enrichment for their
predicted target gene sets. For example, the motif for ZNF238
was associated with genes involved in mitogen-activated
protein kinase (MAPK) signaling, including nuclear factor
of kappa light polypeptide gene enhancer in B cells 1
(NFKB1). This motif has increased activity in children with
CA compared with CTRLs and even higher activity in chil-
dren with SA. The proximal promoter regions of genes
involved in the MAPK and Jun kinase cascades were also en-
riched for the TFAP2B motif, which has increased activity in
children with SA versus those with CA. Interestingly, the
ELK1,4_GABP{A,B1} motif, which has decreased motif
activity in both children with CA and those with SA versus
CTRLs, was found in the promoters of a large number of ri-
bosomal proteins, as well as proteins involved in RNA trans-
port and the spliceosome.
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FIG 2. Expression and support for 3 differentially expressed novel TSSs validated by means of RT-PCR and
Sanger sequencing. Only spliced expressed sequence tags (ESTs) supporting the novel TSS are shown.
A, Alternative first exon for ARHGAP15 used by 2 novel isoforms. B, Alternative first exon for NDEL1.
C, Novel transcript, possibly an isoform of the lincRNA LINC00937. tpm, Tags per million reads.
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TABLE IV. Top 10 significant TF motifs in the promoter region
(21000 to 1200 bp) from MARA for the pairwise comparisons
between sample groups
Motif Score Adjusted P value
Children with SA vs those with CA
NKX6-1,2 23.51 3.13E-04
XCPE1{core} 25.79 1.16E-03
ZNF148 25.37 1.84E-03
NFY{A,B,C} 25.70 4.21E-03
MYF family 5.53 1.06E-04
BREu{core} 6.06 1.88E-03
ESR1 5.47 2.50E-03
MAFB 6.22 2.69E-03
ZBTB6 5.44 4.14E-03
ZNF238 4.47 5.37E-03
Children with CA vs CTRLs
TLX1..3_NFIC{dimer} 26.17 3.11E-03
TFCP2 27.22 6.10E-03
MAFB 25.03 9.53E-03
ELK1,4_GABP{A,B1} 26.45 1.01E-02
HMX1 25.18 1.17E-02
GATA4 25.79 2.19E-02
STAT5{A,B} 7.77 1.14E-03
RUNX1..3 5.53 1.44E-03
LMO2 5.69 2.97E-03
ZNF238 5.40 2.11E-02
Children with SA vs CTRLs
TLX1..3_NFIC{dimer} 26.69 2.75E-03
LMO2 25.61 4.40E-03
TFCP2 29.32 6.43E-03
ELK1,4_GABP{A,B1} 25.60 1.19E-02
MAFB 26.21 1.53E-02
AHR_ARNT_ARNT2 26.01 2.26E-02
STAT5{A,B} 5.18 1.49E-03
RUNX1..3 7.75 1.62E-03
ZNF238 4.47 1.22E-02
HMX1 5.21 1.71E-02
A negative score implies lower motif activity in the first group, and a positive score
implies higher activity (see the Methods section in this article’s Online Repository).
{core}, Core promoter element; {dimer}, protein dimer.
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We analyzed gene expression using CAGE in peripheral blood
leukocytes from children with CA, children with SA, and CTRLs.
We found that they have distinct gene expression profiles with
implications for disease biology and that these differences are
partly explained by the underlying regulatory TF networks. Gene
network analysis identified decreased glucocorticoid receptor
signaling and increased activity of the MAPK and Jun kinase
cascades in children with SA.Many putative novel transcripts and
TSSs were differentially expressed, and 77% (10/13) of those
selected for experimental validation could be detected by using
RT-PCR.
Pairwise comparison between sample groups identified 1305
significantly differentially expressed TCs, 1029 of which
matched 816 known genes. This is similar to the number of
differentially expressed genes in microarray data previously
reported for a cohort in which these samples were included.21
Although the microarray study only identified activation of NK
cell–mediated cytotoxicity in children with CA, we here found
upregulation of different gene sets within this pathway for both
children with CA and those with SA compared with CTRLs.Because the increased blood neutrophil count in children
with SA is likely to affect gene expression profiles, we also
analyzed the CAGE data using GLMs to account for differ-
ences in leukocyte composition. Some processes, including up-
regulation of NK cell–mediated cytotoxicity and leukocyte
migration, as well as downregulation of ribosomal proteins,
in children with SA remained significant, even after
adjustment.
The overlap of significantly differentially expressed genes
between CAGE and microarray analysis was surprisingly small
(approximately 5%). Although earlier work also found relatively
large differences between these methods,39 a comparison of log2
fold changes irrespective of P values demonstrated a reassuring
overrepresentation of concordant versus discordant changes in
gene expression (see Table E12 in this article’s Online Repository
at www.jacionline.org). One contrasting finding is the
upregulation of bitter taste receptor genes in children with SA
in the microarray study.21 These genes are localized in a cluster
on chromosome 12, overlapping the PRR4/PRH1 genes, and
alternative splicing of the PRR4/PRH1 transcripts results in
multiple isoforms encompassing different bitter taste receptor
genes.23We found a fewCAGE tags within this locus, but a strong
TSS signal closely upstream of PRR4/PRH1, which might be the
promoter for the overlapping bitter taste receptors. In agreement
with the microarray study, we found that this promoter is
significantly overexpressed in children with SA compared with
CTRLs.21 Irrespective of the differences, we see a number of
advantages of using CAGE over microarrays: (1) a markedly
improved separation of sample groups by differentially
expressed TCs, as shown by using hierarchical clustering; (ii)
the ability to explore transcriptional complexity, leading to
identification of differentially expressed novel TSSs; and
(iii) sensitive detection and reliable quantification of coding and
noncoding transcripts, where especially the latter are often lowly
expressed.
The current literature contains little data on severe asthma for
comparison, but a recent study on adults reported activation of
CD81 but not CD41 T cells in patients with severe asthma,
whereas patients with nonsevere asthma did not differ from
CTRLs.16 The CD81 T cells from patients with severe and those
with nonsevere asthma could also be separated by clustering on
both of our sets of differentially expressedmarker transcripts. Inter-
estingly, both of the cited studies reported extensive deregulation of
noncoding RNAs in patients with severe asthma.16,21 Three of our
10 validated novel transcripts are putative long noncoding RNAs:
one TSS upstream of an annotated long intergenic noncoding
RNA (lincRNA) and 2 antisense transcripts. The first TSS was up-
regulated in childrenwith SA, even after adjustment for cell counts.
GENCODE-annotated noncoding RNAs upregulated in patients
with SA included nuclear paraspeckle assembly transcript 1
(NEAT1) and PINT (AC058791.2), a lincRNA recently associated
with p53 signaling.40
Because asthma primarily affects the airways, it would be
informative to analyze gene expression in cells from the
respiratory tract, including inflammatory cells, bronchial
epithelium, and smooth muscle. Bronchoscopies, including
bronchial biopsy specimens, were not needed for the diagnosis
of asthma, and the procedure would neither have been easy nor
ethically defensible for these children, especially not for
patients with severe asthma. Here we instead used total
leukocytes from peripheral blood, a sample source that is easy
FIG 3. MARA identifies the TF network underlying differential gene expression between children with CA
and those with SA, which are here significant motifs in the promoter region (21000 to1200 bp). Node color
corresponds to fold change (blue, lowermotif activity in patients with SA; red, higher activity), and node size
is inversely proportional to P value. Edge color reflects gene-specific motif activity (darker equals higher
activity [ie, stronger regulatory effect]). Target genes are represented by green circles for TFs, and yellow
circles for other genes.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2015
646 PERSSON ET AL
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 3
PERSSON ET AL 647to obtain and store and well suited for biomarker development.
These data provide a wealth of information on the blood
transcriptome that could be expanded, such as through studies
of alternative promoter use and functional testing of novel
transcripts and transcript isoforms. However, the different
results from conventional and GLM differential expression
analysis stress the importance of appropriately handling differ-
ences in sample cell composition when sorted cell populations
are unavailable.
In summary, the clear separation of children with CA and those
with SA shows the promise of gene expression profiling for the
development of biomarkers given precisely posed clinical
questions and appropriate validation cohorts. Differences in the
disease biology of the 2 groups, as revealed by differential
expression of both known and novel transcripts, support the need
for novel therapeutic approaches.
We thank Dr Efthymios Motakis, Division of Genomic Technologies,
RIKEN Center for Life Science Technologies, Yokohama, Japan, for his
expert advice on statistical analysis using GLMs.
Key messages
d Circulating leukocytes from children with CA and those
with SA have distinct gene expression profiles.
d Gene network analysis identified decreased glucocorticoid
receptor signaling and increased activity of the MAPK
and Jun kinase cascades in children with SA.
d The results suggest that it would be possible to develop
molecular biomarkers for SA and support the need for
novel therapeutic approaches in this group of patients.
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